Related Experiment Video
Updated: Jul 11, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
A comparison of esmolol and diltiazem for heart rate control during coronary revascularisation on beating heart
1Department of Cardiac anaesthesia and Cardiac Surgery Cardiothoracic Centre, All India Institute of Medical Sciences, New Delhi, India. sancha@medinst.ernet.in.
Insights
Esmolol provided superior heart rate control during coronary artery revascularization surgery but increased pulmonary artery pressure. Diltiazem offered hemodynamic benefits, making it potentially better for hypertensive patients.
Area of Science:
- Cardiovascular Surgery
- Anesthesiology
- Pharmacology
Background:
- Coronary artery revascularization without cardiopulmonary bypass requires precise hemodynamic management.
- Controlling heart rate and blood pressure is crucial during surgical anastomosis.
Purpose of the Study:
- To compare the efficacy of esmolol and diltiazem in controlling heart rate and hemodynamics during off-pump coronary artery revascularization.
- To evaluate the safety and potential adverse effects of each agent in this surgical context.
Main Methods:
- Prospective study of 60 adult patients with coronary artery disease undergoing off-pump revascularization.
- Randomized groups: Group A received esmolol (loading dose 50 microg/kg, infusion 100 microg/kg/hr); Group B received diltiazem (loading dose 0.15 mg/kg, infusion 5 mg/hr).
- Hemodynamic parameters including heart rate, systemic vascular resistance, and pulmonary artery pressures were monitored.
Main Results:
- Esmolol group achieved significantly better heart rate control (51.4 beats/min) compared to diltiazem (69.6 beats/min) (p <0.01).
- Esmolol caused significant increases in mean pulmonary artery pressure and pulmonary vascular resistance.
- Diltiazem decreased systemic vascular resistance, mean pulmonary artery pressure, and pulmonary artery wedge pressure, with a reduced right ventricular stroke work index.
Conclusions:
- Esmolol offers superior heart rate reduction but necessitates caution due to potential pulmonary hypertension, especially in patients with right ventricular dysfunction.
- Diltiazem may be a preferable option for hypertensive patients undergoing off-pump coronary revascularization due to its favorable systemic hemodynamic effects.
Abstract:
This prospective study compared control of heart rate and haemodynamics during coronary artery revascularization without cardiopulmonary bypass using either esmolol or diltiazem. Sixty adult patients with one or two vessel coronary artery disease, were randomly divided into 2 groups. Group A (n=30) received a 50 microg/kg/ loading dose of esmolol followed by a 100 microg/kg/hr infusion, for control of heart rate during surgical anastomosis of the coronary vessel. Group-B (n=30) received 0.15 mg/kg of diltiazem as a loading dose followed by a 5 mg/hr infusion for heart rate control, during the anastomosis. It was seen that heart rate control was better in group A, 51.4 +/- 1.3 beats/min, (p <0.01) than in group B, 69.6 +/- 3.0 beats/min (p <0.05), as compared to baseline values of 80.6 +/- 12.1 beats/min in group A and 82.4 +/- 10.6 beats/min in group B respectively. Systemic vascular resistance and pulmonary artery wedge pressure were unchanged in group A but mean pulmonary artery pressure and pulmonary vascular resistance were significantly raised. Group B patients had decreased systemic vascular resistance, mean pulmonary artery pressure and pulmonary artery wedge pressure, and reduced right ventricular stroke work index at the time of distal coronary anastomosis. We concluded that although esmolol provided dramatically slower heart rates, during surgery, the resulting elevations in mean pulmonary artery pressure and pulmonary vascular resistance would require caution if used in patients with underlying right ventricular dysfunction from ischaemia or infarction. Diltiazem by virtue of its effects on systemic vascular resistance, cardiac output, and lowering of mean arterial pressure may be a better choice in hypertensive patients.
More Related Videos
Related Concept Videos
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Dysrhythmias VI: Management of Dysrhythmias
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers

